DOCSLIB.ORG

Design Requirements for Anatomical Pathology Departments Guideline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Design Requirements for Anatomical Pathology Departments Guideline Design Requirements for Anatomical Pathology Departments Guideline Guideline Design Requirements for Anatomical Pathology Departments NSWHP_PG_019 Contents Contents ......................................................................................................................................... 1 1. Purpose ................................................................................................................................... 3 2. Background.............................................................................................................................. 3 3. Scope ...................................................................................................................................... 3 4. Definitions ................................................................................................................................ 4 5. Policy Statement ....................................................................... Error! Bookmark not defined. 5.1 Key Planning Considerations................................................................................................ 4 5.2 Design Requirements of the Histopathology Laboratory ....................................................... 4 a) Specimen Reception/Accession ............................................................................................... 5 b) Fresh Tissue and Frozen Section ............................................................................................ 6 c) Cut-Up ..................................................................................................................................... 6 d) Tissue Processing.................................................................................................................... 7 e) Chemical Preparation and Decanting ....................................................................................... 8 f) Specimen Storage, Retrieval and Archiving ............................................................................. 8 g) Embedding, Sectioning and Staining ....................................................................................... 8 h) Embedding .............................................................................................................................. 9 i) Tissue Sectioning .................................................................................................................... 9 j) Tissue Staining and Coverslipping ......................................................................................... 10 k) Case Assembly, Checking and Case Allocation ..................................................................... 10 l) Slide Scanning for Whole Slide Imaging ................................................................................ 11 m) Immunohistochemistry........................................................................................................ 11 5.3 Storage .............................................................................................................................. 12 a) Chemical and Flammable Stores ........................................................................................... 12 b) Consumable Stores ............................................................................................................... 12 c) Slide and Block Storage ......................................................................................................... 12 5.4 Specialised Testing ............................................................................................................ 13 a) Cytology ................................................................................................................................. 13 b) Immunofluorescence .............................................................................................................. 14 c) Molecular testing of cancer .................................................................................................... 14 d) Electron Microscopy ............................................................................................................... 15 e) Autopsy .................................................................................................................................. 15 5.5 Design Requirements of the Histopathology Department ................................................... 15 a) Reporting and Consulting....................................................................................................... 15 b) Trainees ................................................................................................................................. 16 c) Conference and Teaching Areas ............................................................................................ 17 d) Administrative Office .............................................................................................................. 17 e) Staff Safety ............................................................................................................................ 18 f) Staff Facilities ........................................................................................................................ 18 6. Roles and Responsibilities ..................................................................................................... 18 7. Legal and Policy Framework .................................................................................................. 18 8. Review ................................................................................................................................... 19 9. Risk ....................................................................................................................................... 19 10. Further Information ............................................................................................................. 19 11. Version History ................................................................................................................... 19 Appendix A – Tissue Pathology Functional Components Diagram ................................................ 20 Page 2 of 20 Approver: Executive Director Clinical Streams, Version Number: V1.0, Publication Date: 4/12/2019 This document is subject to change and a printed copy may not be up to date. The current version is only available online in the NSW Health Pathology Policy Library Guideline Design Requirements for Anatomical Pathology Departments NSWHP_PG_019 1. Purpose To define the design requirements for future developments of Anatomical Pathology Departments within NSW Health Pathology. 2. Background Anatomical Pathology (AP) involves the study of human tissues for diagnosis and monitoring of disease or directing treatment. This encompasses the study of: • Whole organs or samples of tissue in histopathology and electron microscopy • Isolated cells in cytopathology • The components of cells as in immunohistochemistry and • Somatic genomics. An AP Department contains a “clean” consultation/microscopy area including workspace for pathologists, registrars, cytologists and laboratory managers. Case reporting is performed by specialist anatomical pathologists examining tissue or cells at microscopic level and this comprises the “testing” component of AP. All cases are reported by a specialist anatomical pathologist except normal gynaecological cytology (LBC). The activities of the anatomical pathology laboratory may allow for flexibility in service design, including relocation of some activity off site. On site services should include specimen receipt and macroscopic examination of larger resection or biopsy specimens, and this is encompassed in the onsite preparation of specimens for the pathologist to examine, although other technical activity such as tissue processing and slide preparation may be performed off-site NSW Health Pathology AP Departments are hospital based and process a significant volume of specimens including a high volume of large and complex surgical specimens. The Australasian Health Facility Guidelines (AusHFG) state that there is a need to physically confine a laboratory based upon the physical, chemical or biological hazards generated in laboratories including AP. These laboratories must be physically separated from other laboratory work areas by walls and doors including air handling from other laboratory work areas. This guideline should be read in conjunction with NPAAC Requirements for Medical Pathology Services 2018 Standards S7A.1 and S7A.2 and work, health and safety (WHS) requirements. 3. Scope This guideline applies to all NSW Health Pathology AP Departments. It should be noted that some customisation may be necessary to meet local requirements. Mortuary facilities have specific design requirements that are not within the scope of this guideline. Electron microscopy laboratories have specific requirements and have not been specifically addressed in this document. Page 3 of 20 Approver: Executive Director Clinical Streams, Version Number: V1.0, Publication Date: 4/12/2019 This document is subject to change and a printed copy may not be up to date. The current version is only available online in the NSW Health Pathology Policy Library Guideline Design Requirements for Anatomical Pathology Departments NSWHP_PG_019 4. Definitions Clean area: A clean area is an area not used for the handling or processing of biological specimens. Cytology: The study of tissue at an individual cell level.
Load more

Recommended publications
  • Health Sciences Center
    Faculty of Allied Health Sciences Handbook: 2020-2021 KUWAIT UNIVERSITY HEALTH SCIENCES CENTRE 1 | P a g e KUWAIT UNIVERSITY HEALTH SCIENCES CENTRE FACULTY OF ALLIED HEALTH SCIENCES Established: 1982 HANDBOOK 2020-2021 2 | P a g e Department of MEDICAL LABORATORY SCIENCES [MLS] 3 | P a g e DEPARTMENT OF MEDICAL LABORATORY SCIENCES Medical Laboratory Sciences offers opportunities for those interested in biological and chemical sciences, leading to a career in the health service or in research. Medical laboratory scientists are professionals who perform laboratory tests and analyses that assist physicians in the diagnosis and treatment of patients. They also assist in research and the development of new laboratory tests. The various studies include chemical and physical analysis of body fluids (clinical chemistry and urinalysis); examination of blood and its component cells (haematology); isolation and identification of bacteria, fungi, viruses and parasites (clinical microbiology and parasitology); testing of blood serum for antibodies indicative of specific diseases (immunology and serology) and collection, storage of blood, pretransfusion testing and other immunohaematological procedures (blood banking). In addition, medical laboratory scientists prepare tissues for histopathological, cytological and cytogenetic examination. They must know the theory and scientific fundamentals as well as the procedures for testing. Medical laboratory scientists work in hospital clinical laboratories, medical schools, research institutions, public health agencies and related organizations. MISSION AND OBJECTIVES Mission The mission of the Department of Medical Laboratory Sciences is to educate and train skillful, knowledgeable and committed Medical Laboratory Scientists who have breadth of knowledge and competence in the various aspects of Medical Laboratory Sciences, who shall adhere to professional ethics, and who can contribute successfully as Medical Laboratory Scientists in the health care team.
    [Show full text]
  • Anatomical Pathology Residency Program PROGRAM DESCRIPTION and OUTLINE – Non-CBME
    Anatomical Pathology Residency Program PROGRAM DESCRIPTION AND OUTLINE – Non-CBME The Anatomical Pathology Residency Program at the Schulich School of Medicine & Dentistry at Western University is a five year program based at the London Health Sciences Centre, University Hospital. There is a structured schedule of rotations designed to ensure that residents are able to fulfill all of the goals and objectives of training and acquire the necessary knowledge base to practice as competent consultant pathologists. There are also elective opportunities that permit the resident to tailor the program to their own needs and goals. There is a comprehensive education program, with various rounds and teaching sessions that supplement the rotations. Program Organization Rotations (4 week blocks) General Surgery 2 blocks General Internal Medicine 1 block Respirology or Nephrology 1 block Gynecologic Oncology 1 block Radiation Oncology 1 block Emergency Medicine 1 block PGY1 Urology 1 block Gastroenterology 1 block Hematology Oncology 1 block Anatomical Pathology 1 block Otolaryngology 1 block Pediatric Medicine 1 block The PGY1 year is a broad based clinical year designed to satisfy the specialty-specific objectives and Medical Council of Canada Qualifying Examination Part II requirements. Rotations are planned in conjunction with the resident in order to meet individual needs (the above-mentioned rotations may be changed). During this year, the resident attends the Pathology Academic Half Day, Department of Pathology Grand Rounds, and the Department
    [Show full text]
  • Brain – Necrosis
    Brain – Necrosis 1 Brain – Necrosis 2 Brain – Necrosis Figure Legend: Figure 1 Appearance of a thalamic infarct at low magnification, identified by pallor within the zone of the black arrows, in an F344/N rat. The dentate gyrus of the hippocampus is identified by a white arrow. This infarct was the result of an arterial embolus (arrowhead), shown at higher magnification in Figure 2. Figure 2 Arterial embolus from Figure 1 at higher magnification, in an F344/N rat. Figure 3 Acute necrosis of the posterior colliculus, a bilaterally symmetrical lesion (arrows), in the whole mount of a section in a male F344/N rat from an acute study. This resulted from the selective vulnerability of this brain region to toxin- induced impaired energy metabolism. The arrowhead identifies necrosis of the nucleus of the lateral lemniscus. Figure 4 Similar regionally selective bilateral brain necrosis of the parietal cortex area 1 (blue arrow), thalamus (arrowhead), and retrosplenial cortex (white arrow) in a treated male F344/N rat from an acute study, all resulting from the same toxic compound as used in Figure 3. Figure 5 Unusual form of malacia (total regional necrosis) of the spinal cord in the dorsal spinal funiculi (arrow) in a female F344/N rat from a chronic study. Figure 6 A cortical infarct with gliosis and capillary hyperplasia (arrow) from a male B6C3F1 mouse in a chronic study. Figure 7 A more advanced stage of cortical infarction (arrows) in a treated female B6C3F1 mouse from a chronic chronic inhalation study. Figure 8 Morphology of an infarct of known duration (arrow) in an F344/N rat with experimental infarction.
    [Show full text]
  • 2019-General-Pathology-Faq.Pdf
    FREQUENTLY ASKED QUESTIONS – 2019 Program: GENERAL PATHOLOGY Specialty/Field Questions: 1. a) What are some strengths about your specialty? What draws and keeps people in your specialty? • The opportunity to understand the nature of disease in an in-depth way that isn’t achieved in any other specialty. You get to practice scientific diagnostic medicine over a broad range of subjects and you have a fair degree of control over your schedule. You are very much a part of the team taking care of the patient (it just isn’t as obvious!), and this is becoming even more apparent in the era of precision medicine. • Although there is limited direct contact with patients, there is a great deal of contact with a variety of clinicians outside the laboratory as well as with physician, PhD, and technical staff colleagues within the laboratory. We get satisfaction from the interactions we have with others, and knowing that we are helping a clinician take the next step in diagnosing or treating a patient. The stereotypical image of the hermit- like pathologist who stays in their office and never talks to anyone is rapidly disappearing in today’s pathology practice. b) What are some common complaints about your specialty? • There is limited direct clinical contact – you’ll never have an office full of patients who regard you as their doctor and most pathologists have a hospital-based practice which can limit professional autonomy. • You often have to sit/stand at a microscope and/or computer a lot, so sometimes you need to get creative about staying active during the day.
    [Show full text]
  • Role of Histopathological Examination in Medicolegal Autopsies in Unravelling Pathology Section Precise Causes of Mortality
    DOI: 10.7860/NJLM/2021/48233:2522 Original Article Role of Histopathological Examination in Medicolegal Autopsies in Unravelling Pathology Section Precise Causes of Mortality DIVYA SHARMA1, ANSHU GUPTA2, KHUSHBOO DEWAN3, KARSING PATIRI4, KUSUM GUPTA5, USHA RANI SINGH6 ABSTRACT Histopathological examination was performed in 96 cases out of Introduction: Medicolegal autopsies are performed to determine which 10 were excluded due to autolysis (n=86). Haemotoxilin the cause and manner of death. Histopathological examination and Eosin (H&E)-stained slides were examined and special is reserved for only those cases where Cause Of Death (COD) is stains and Immunohistochemistry (IHC) applied wherever not readily apparent on autopsy. However, there are conflicting required. Gross and histopathological findings were recorded views regarding the utility of histopathological examination in along with autopsy findings and clinical history. The results were medicolegal cases. tabulated and statistical analysis was done using the Chi-square and Fischer’s test to look for any significance and association Aim: To examine the role of histopathological examination in between gross and microscopic findings in various organs. The unravelling specific causes of mortality in two settings: 1) where p-value of <0.05 was considered significant. collaborative clinical history and gross autopsy findings were available; 2) where definitive cause could be discovered only Results: Histopathological examination was conclusive in at the time of microscopic examination, thus altering its legal ascertaining the specific COD in 30/86 cases (35%). These were implications. categorised as pulmonary causes (27) including one case each Materials and Methods: This was a retrospective observational of fat embolism and Amniotic Fluid Embolism (AFE) and cardiac study including all medicolegal autopsy cases, in which causes (3).
    [Show full text]
  • Histopathology
    INTERNATIONAL CLINICAL FELLOWSHIP TRAINING IN HISTOPATHOLOGY © Royal College of Physicians of Ireland, 2019 1 This curriculum of training in Histopathology was developed in 2015 and undergoes an annual review by Prof Cecily Quinn, Clinical Lead, Leah O’Toole, Head of Postgraduate Training and Education , and by the Histopathology Training Committee. The curriculum is approved by the Faculty of Pathology. Version Date Published Last Edited By Version Comments 5.0 01 July 2019 Keith Farrington None © Royal College of Physicians of Ireland, 2019 2 Histopathology International Table of Contents Table of Contents INTRODUCTION ............................................................................................................................................... 4 GENERIC COMPONENTS ................................................................................................................................... 7 GOOD PROFESSIONAL PRACTICE ................................................................................................................................. 8 INFECTION CONTROL .............................................................................................................................................. 10 SELF-CARE AND MAINTAINING WELL-BEING ............................................................................................................... 12 COMMUNICATION IN CLINICAL AND PROFESSIONAL SETTING .......................................................................................... 14 LEADERSHIP .........................................................................................................................................................
    [Show full text]
  • Cytopathology Pathology
    New York State Department of Health Clinical Laboratory Standards of Practice Specialty Requirements by Category Cytopathology Pathology Cytopathology Standard Guidance Cytopathology Standard of Practice 1 (CY S1): Staining of While the actual staining technique may vary depending on the Gynecologic Slides type of stain used and the modification of the method, any modification must include the four main steps of the standard The laboratory must use a Papanicolaou or modified Papanicolaou method: fixation, nuclear staining, cytoplasmic Papanicolaou staining method for gynecologic cytology slides. staining, and clearing. Cytopathology Standard of Practice 2 (CY S2): Prevention 10 NYCRR Subparagraph 58-1.13(b)(3)(iii) requires separate of Cross Contamination Between Specimens During the staining of gynecologic and non-gynecologic slides. Staining Process In general, all stains and solutions should be filtered or The laboratory must ensure that: changed at intervals appropriate to the laboratory’s workload to a) gynecologic and non-gynecologic cytology slides are ensure staining quality meets the laboratory’s pre-established stained separately; and criteria. Stain quality should be verified every eight (8) hours for laboratories that operate twenty-four (24) hours a day. b) non-gynecologic cytology slides that have high potential for cross-contamination are stained separately from b) A toluidine blue stain may be used to determine the other non-gynecologic slides, and the stains and cellularity of non-gynecologic specimens. solutions are filtered or changed following staining. Cytopathology Standard of Practice 3 (CY S3): Targeted Slides reviewed as part of ten (10) percent re-examination must Re-examination be included in the workload limit of the cytology supervisor or the cytotechnologist performing the re-examination.
    [Show full text]
  • Anatomical Pathology
    Timely and accurate pathology results are Pathology disciplines critical to the functioning of our entire medical system. 70% of all diagnoses are made using a pathology test. All chronic conditions require monitoring via pathology testing. Pathologists play a Pathology informs the clinical decisions of medical practitioners much wider role than just diagnosing cancer, and work across a range across the healthcare spectrum. of different specialities, in addition to anatomical pathology. These include: Given its critical role, the risks of not adequately supporting Pathologists are Indispensable to Quality Patient Care a strong national pathology system are: Chemical pathology, which deals with the entire range of disease, • Incorrect diagnoses; and encompasses detecting changes in a number of substances in • Delayed diagnoses; blood and body fluids (such as electrolytes, enzymes and proteins); • Patients receiving incorrect treatment; Forensic pathology, which seeks to investigate and define the cause • Tumours inadequately or inappropriately treated (e.g. of unexpected death; unnecessary surgery); and Genetics, which looks at chromosomes and DNA from cells to • Possible early patient death. diagnose genetic diseases; These issues may impact upon the physical, emotional and Haematology, which deals with diseases that affect the blood such as financial well-being of individual patients, their families and the anaemia, leukaemia, lymphoma, clotting or bleeding disorders as well community at large. as management of blood transfusions; Immunopathology, which deals with the diagnosis and management As the peak body representing the profession, the RCPA of conditions in which the immune system does not function properly; believes the underlying principles of a world class pathology service are: Microbiology, which deals with diseases caused by infectious agents • A commitment to patient safety and quality such as bacteria, viruses, fungi and parasites; and • A highly trained and sufficiently resourced workforce General pathology, which covers the profession as a whole.
    [Show full text]
  • Histopathology and Cytopathology of Cervical Cancer
    Disease Markers 23 (2007) 199–212 199 IOS Press Histopathology and cytopathology of cervical cancer David Jenkins Glaxo Smith Kline Biologicals, Rixensart, Belgium University of Nottingham, Nottingham, UK E-mail: [email protected] 1. Introduction 30–34 y. Despite this, because of the difficulties and costs of this approach, globally, there are almost half a Histopathology and cytopathology form the scientif- million cases of cervical cancer each year. ic and clinical basis for current prevention and treat- Concurrently with the enormous success of cytolog- ment of cervical cancer. Histopathology determines ical screening, there has been increasing knowledge of treatment of cancer and precancer through classifying the challenges of the limited reproducibility of the di- into a diagnosis the patterns of microscopic organiza- agnoses, of the complex relationships between cytolog- tion of cells in tissue sections from biopsy or surgical ical and histological diagnosis and the natural history specimens. Although morphological concepts of cer- of cervical precancer, particularly the driving role of vical cancer and precancer evolution are giving way infection with genital human papillomavirus (HPV). to viral and molecular knowledge, histopathology al- This review focuses on the concepts and terminology so remains important as the most widely used clinical used in classifying morphological changes of cervical endpoints by which the performance of new techniques precancer and HPV infection, how this links to natu- for cervical cancer prevention are currently evaluated. ral history through information from cervical screening Cervical cytopathology studies exfoliated cells taken and more recent cohort studies of HPV infection. It from the surface of the cervix and is the main method addresses the issues around the performance character- of cervical screening in successful cervical cancer pre- istics (reproducibility and accuracy) of cytopathology vention programmes.
    [Show full text]
  • Quality Assurance Program for Anatomical Pathologists Printed Copies Are Uncontrolled
    Quality Assurance Assessment Program for Anatomical Pathologists This provincial best practice document is being developed in response to the Cochrane Report recommending a peer review program for pathology with results reported to the Health Authority Quality Committee, BC’s Agency for Pathology and Laboratory Medicine and the Diagnostic Accreditation Program, when appropriate. The program has been developed with input from the provincial Anatomic Pathology Working Group, along with review of current provincial practices and peer reviewed publications, specifically the Pan- Canadian Quality Assurance Recommendations for Interpretive Pathology. The program is designed to be proactive where quality activities are embedded directly into the clinical practice of anatomic pathologists via the Laboratory Information System (LIS), allowing standardized quality assurance data to be captured, reported, reviewed and discrepancies reported for follow up corrective action through standardized quality improvement processes. Objective: Develop a standardized approach to Quality Assurance (QA) in interpretive pathology for use by all anatomic pathologists. Capture pathologist QA activities, and provide meaningful statistics to individual pathologists, the Laboratory quality committee, health authority medical administration and the Agency to allow year over year comparisons by pathologist, facility, HA and comparisons across the province. To build a provincial anatomic pathology culture based on sustainable high quality diagnostic services to enable the enhancement of patient safety. To ensure the public have confidence in British Columbia’s anatomic pathology service regardless of geographic location or jurisdiction. Goal: For the activities related to all anatomic pathologists caseload be involved in a review, which is measurable and comparable to a standard baseline. Where appropriate, reviews will target surgical pathology, cytology and autopsy services, including all related ancillary testing.
    [Show full text]
  • A Case of Neurofibromatosis 2 Presenting with a Mononeuritis Multiplex
    Journal of Neurology, Neurosurgery, and Psychiatry 1992;55:391-393 391 SHORT REPORT J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.55.5.391 on 1 May 1992. Downloaded from A case of neurofibromatosis 2 presenting with a mononeuritis multiplex T J Kilpatrick, R J Hjorth, M F Gonzales Abstract forearm extensors. There was weakness of the A patient with neurofibromatosis 2 had an intrinsic muscles of the right hand and gener- asymmetrical peripheral neuropathy. A alised weakness of the left arm. The legs were nerve biopsy specimen revealed neuro- also wasted with symmetrical distal weakness. fibromatous changes, and the neuropathy The reflexes were depressed on the right but may have been a direct consequence of normal on the left, except for a depressed ankle neurofibromatosis. An apparent clinical jerk. The right plantar was flexor and the left response to immunosuppressive treat- unresponsive. There was a mild impairment of ment and plasma exchange is also repor- all sensory modalities in the hands and legs, ted. extending to the right knee and to the left anterior superior iliac spine. There were no palpable enlargements along the course of any The term neurofibromatosis defines two peripheral nerves. genetically and phenotypically distinct dis- The results of tests for urea, electrolytes and orders.' Neurofibromatosis 1, or von Reck- liver function, full blood examination and linghausen's disease, is an autosomal domi- random blood glucose and serum calcium, nant disorder with the genetic abnormality phosphate, vitamin B12, and folate concentra- localised to chromosome 17. Typical abnor- tions were all normal. There was no para- malities include cafe-au-lait spots, neuro- proteinaemia, antinuclear antibodies were not fibromas, and Lisch nodules in the iris.
    [Show full text]
  • Histopathology Requisition
    SLUCare PATHOLOGY LABORATORIES HISTOPATHOLOGYFLOW CYTOMETRY REQUISITION REQUISITION HISTOPATHOLOGY: 1402 S. GRAND BLVD., ST. LOUIS, MO 63104 • P: 314-977-7874 • F: 314-977-7898 FLOW CYTOMETRY • PHONE: (314) 977-7864 • FAX: (314) 977-3221 • 1402 S. GRAND BLVD., ST. LOUIS, MO 63104 PATIENT NAME NAME (LAST, (LAST, FIRST, FIRST, MI): MI): DATE OF BIRTH:DATESEX: OF BIRTH: DIAGNOSISSEX: CODE: M F MALE FEMALE DATE OF OF COLLECTION: COLLECTION: TIMETIME OF COLLECTION: ACCESSIONACCESSION #: #: FIXATIVE:BLOCK ID: AM PM AM PM PLACE OF OF SERVICESERVICE SPECIMEN SPECIMEN WAS WAS OBTAINED: OBTAINED: H #:H #: INPATIENTINPATIENT ENTER ENTER ADMIT ADMIT DATE: DATE: _____/_____/_____/ / OUTPATIENT OUTPATIENTASC OFFICE ASC OFFICE REFERRING INSTITUTION: INSTITUTION: SPECIMENSPECIMEN TYPE: TYPE: BLOCKFIXATIVE: #: ADDRESS: CITY:CITY: STATE:STATE: ZIPZIP CODE: CODE: PHONE: FAX:FAX: REFERRINGREFERRING PHYSICIAN PHYSICIAN SIGNATURE: DATE:DATE: AVAILABLEIMMUNOHISTOCHEMISTRY TESTING AND IN-SITUACCEPTABLE HYBRIDIZATION SPECIMENS P Flow Cytometry ImmunophenotypingCPT P CPT P Bone Marrow CPT P CPT CODE CODE CODE CODE Actin(Leukemia/Lymphoma) (SMA) 88342 CD31 88342 (SodiumER Heparin – green88342 tops)MUM-1 88342 AE1/AE3 Keratin (Pan CK) 88342 CD33 88342 (EDTAFactor VIII – purple tops)88342 Myeloperoxidase 88342 Hematopathology Consult ALK-1 88342 CD34 88342 Factor XIII 88342 MyoD1 88342 Peripheral Blood AlphaCD34+ Fetoprotein Stem (AFP) Cell Enumeration88342 CD43 88342 GCDFP-15 (Brst-2) 88342 Myogenin 88342 AMACR (P504S) 88342 CD45 (LCA) 88342 (SodiumGFAP Heparin – green88342 tops)Myosin 88342 Annexin 88342 CD56 88342 (EDTAGlutamine Synthetase – purple tops)88342 Neu-N 88342 T cell Lymph Subset Panel BAPP(CD3, (ALZ Precursor CD4, Protein) CD8, Ratio)88342 CD57 88342 Glypican 3 88342 Neurofilament 88342 Bcl-2 88342 CD61 88342 BodyH.
    [Show full text]